Atossa Therapeutics Inc (ATOS)
Atossa Therapeutics is a clinical-stage biopharmaceutical company seeking to develop medicines in areas of oncology and infectious diseases, with a focus on breast cancer, other breast conditions and COVID-19. Co.'s drug under development for breast cancer and other breast conditions is Endoxifen which is being developed primarily in two settings: one to reduce tumor cell activity in breast cancer patients in the neoadjuvant setting, meaning prior to surgery; and another to reduce dense breast tissue in women. Co.'s two COVID-19 drugs under development are: AT-H201, an inhalation therapy for COVID-19 patients; and AT-301, a nasal spray for COVID-19 patients for at-home use.
|
March 28, 2024 4:22 AM Eastern
Strong Buy (4.00 out of 4)
98th percentile
|
|